Proactive Investors - Run By Investors For Investors

AstraZeneca reports positive top-line data from phase III COPD trial

The KRONOS trial showed that Astra’s PT010 inhaler can improve lung function in patients with moderate to severe chronic obstructive pulmonary disease
lungs
Respiratory is a key area of focus for AstraZeneca

AstraZeneca PLC (LON:AZN) has reported positive top-line data from a phase III trial which compared its PT010 therapy for chronic obstructive pulmonary disease (COPD) against existing treatments.

The FTSE 100 drugmaker said its triple combination inhaler “demonstrated a statistically significant improvement” in eight of the nine lung function primary endpoints compared with dual combo therapies.

READ: Immuno-oncology: What does 2018 have in store for Big Pharma and their cancer immunotherapies?

COPD is a common condition that mainly affects middle-aged or older adults who smoke and can block airflow to the lungs causing breathing difficulties.

Astra added that no unexpected safety or tolerability signals for PT010 were identified in the trial.

Regulatory submissions in Japan and China are expected in the second half of this year, followed by potential submissions in the US and Europe in 2019.

“We are encouraged by the results of the KRONOS trial that has demonstrated PT010's efficacy in improving lung function and look forward to the ETHOS exacerbation trial results in 2019 that will further characterise the role of this potential treatment for patients with COPD,” said chief medical officer Sean Bohen.

READ: AstraZeneca gets approval for two cancer and asthma treatments in Japan

Professor Kalus Rabe, the co-ordinating investigator of the trial, said: “With the KRONOS trial, we are seeing the potential of PT010 as a triple combination therapy for COPD.

“I expect the triple class of medicines to play an increasingly important role in addressing the needs of the many COPD patients who are currently undertreated or are receiving triple combination therapy as separate medicines in multiple devices.”

View full AZN profile View Profile

AstraZeneca Timeline

Related Articles

test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme
Antigens
November 29 2018
The deal with New England Biolabs, signed in October, is expected to secure six-figure royalty sums as soon as next year
man coughing
November 10 2018
Some of the big boys are shifting their focus away from their respiratory drugs, which could open up opportunities for Circassia to in-license them

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use